Brian Orelli, PhD

Fool analysts discuss Corium, Cerulean Pharma, Adamas Pharmaceuticals, and MannKind-competitor Dance Pharma.

Can ANI Pharmaceuticals compete with Teva Pharmaceuticals, Novartis, and the rest of the big generic-drug makers?

Drugmakers like GlaxoSmithKline and Celgene keep snatching them up before they can get a second drug approved. Will it happen to Medivation?

Drugs from Merck and Bristol-Myers Squibb look like they'll be able to compete with offerings from Gilead Sciences, AbbVie, and Johnson & Johnson.

Gilead Sciences, Orexigen, GW Pharma -- the whole industry has taken a bit of a beating.

Pfizer was reportedly interested in buying AstraZeneca taking us back to an era of mega-mergers such as Pfizer-Wyeth and Merck-Schering-Plough.

A rundown of what to expect from Gilead Sciences, Arena Pharmaceuticals, and Biogen Idec.

Let's hope Sarepta Therapeutics doesn't follow in Prosensa and GlaxoSmithKline's footsteps and come crashing down.

GW Pharmaceuticals is more like Biogen, Teva Pharmaceuticals, and Acorda Therapeutics than penny-stock companies hocking medical marijuana.

Gilead Sciences's competition from AbbVie and Merck is just one of the reasons.

What will Amgen do with T-VEC and will it be able to compete with Bristol-Myers Squibb's Yervoy, which is already on the market, and Merck's (NYSE: MRK) experimental anti-PD-1 antibody MK-3475.

Investors often ignore private biotechs because they can't buy shares, but investors in companies such as InterMune and the obesity drug makers -- Arena Pharmaceuticals, VIVUS, and Orexigen -- need to follow their privately-held competitors.

Despite issues, over half of investors in a Motley Fool poll thought MannKind's inhaled insulin, Afrezza, would be approved this week.

Agios Pharmaceuticals presents promising data on AG-221, which is partnered with Celgene.

That's what Arrowhead Research claims, but it should look at Gilead Sciences pricing in developing markets before spouting such inflated numbers.

Amgen, Biogen Idec, Celgene, Gilead Sciences, Regeneron Pharmaceuticals, and Alexion Pharmaceuticals make up 77% of the increase in the biotech sector over the past three years.

Biogen Idec, Gelgene, and GlaxoSmithKine have signed deals with venture capitalists to develop startups that they can purchase later. Johnson & Johnson has taken a different approach to helping startups.

The FDA advisory committee overwhelmingly recommends approving MannKind's Afrezza.

Changing products between clinical trials and submission is never a good idea.

Exelixis' shares got hammered after announing that it was continuing a clinical trial testing Cometriq in prostate cancer. Investors seem to be worried about how well Cometriq might compete with drugs from Johnson & Johnson and Medivation, assuming it's successful when final data is revealed.